Cargando…

Comprehensive target capture/next-generation sequencing as a second-tier diagnostic approach for congenital muscular dystrophy in Taiwan

PURPOSE: Congenital muscular dystrophy (CMD) is a heterogeneous disease entity. The detailed clinical manifestation and causative gene for each subgroup of CMD are quite variable. This study aims to analyze the phenotypes and genotypes of Taiwanese patients with CMD as the epidemiology of CMD varies...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Wen-Chen, Tian, Xia, Yuo, Chung-Yee, Chen, Wan-Zi, Kan, Tsu-Min, Su, Yi-Ning, Nishino, Ichizo, Wong, Lee-Jun C., Jong, Yuh-Jyh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300266/
https://www.ncbi.nlm.nih.gov/pubmed/28182637
http://dx.doi.org/10.1371/journal.pone.0170517
_version_ 1782506159262924800
author Liang, Wen-Chen
Tian, Xia
Yuo, Chung-Yee
Chen, Wan-Zi
Kan, Tsu-Min
Su, Yi-Ning
Nishino, Ichizo
Wong, Lee-Jun C.
Jong, Yuh-Jyh
author_facet Liang, Wen-Chen
Tian, Xia
Yuo, Chung-Yee
Chen, Wan-Zi
Kan, Tsu-Min
Su, Yi-Ning
Nishino, Ichizo
Wong, Lee-Jun C.
Jong, Yuh-Jyh
author_sort Liang, Wen-Chen
collection PubMed
description PURPOSE: Congenital muscular dystrophy (CMD) is a heterogeneous disease entity. The detailed clinical manifestation and causative gene for each subgroup of CMD are quite variable. This study aims to analyze the phenotypes and genotypes of Taiwanese patients with CMD as the epidemiology of CMD varies among populations and has been scantly described in Asia. METHODS: A total of 48 patients suspected to have CMD were screened and categorized by histochemistry and immunohistochemistry studies. Different genetic analyses, including next-generation sequencing (NGS), were selected, based on the clinical and pathological findings. RESULTS: We identified 17 patients with sarcolemma-specific collagen VI deficiency (SSCD), 6 patients with merosin deficiency, two with reduced alpha-dystroglycan staining, and two with striking lymphocyte infiltration in addition to dystrophic change on muscle pathology. Fourteen in 15 patients with SSCD, were shown to have COL6A1, COL6A2 or COL6A3 mutations by NGS analysis; all showed marked distal hyperlaxity and normal intelligence but the overall severity was less than in previously reported patients from other populations. All six patients with merosin deficiency had mutations in LAMA2. They showed relatively uniform phenotype that were compatible with previous studies, except for higher proportion of mental retardation with epilepsy. With reduced alpha-dystroglycan staining, one patient was found to carry mutations in POMT1 while another patient carried mutations in TRAPPC11. LMNA mutations were found in the two patients with inflammatory change on muscle pathology. They were clinically characterized by neck flexion limitation and early joint contracture, but no cardiac problem had developed yet. CONCLUSION: Muscle pathology remains helpful in guiding further molecular analyses by direct sequencing of certain genes or by target capture/NGS as a second-tier diagnostic tool, and is crucial for establishing the genotype-phenotype correlation. We also determined the frequencies of the different types of CMD in our cohort which is important for the development of a specific care system for each disease.
format Online
Article
Text
id pubmed-5300266
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53002662017-02-28 Comprehensive target capture/next-generation sequencing as a second-tier diagnostic approach for congenital muscular dystrophy in Taiwan Liang, Wen-Chen Tian, Xia Yuo, Chung-Yee Chen, Wan-Zi Kan, Tsu-Min Su, Yi-Ning Nishino, Ichizo Wong, Lee-Jun C. Jong, Yuh-Jyh PLoS One Research Article PURPOSE: Congenital muscular dystrophy (CMD) is a heterogeneous disease entity. The detailed clinical manifestation and causative gene for each subgroup of CMD are quite variable. This study aims to analyze the phenotypes and genotypes of Taiwanese patients with CMD as the epidemiology of CMD varies among populations and has been scantly described in Asia. METHODS: A total of 48 patients suspected to have CMD were screened and categorized by histochemistry and immunohistochemistry studies. Different genetic analyses, including next-generation sequencing (NGS), were selected, based on the clinical and pathological findings. RESULTS: We identified 17 patients with sarcolemma-specific collagen VI deficiency (SSCD), 6 patients with merosin deficiency, two with reduced alpha-dystroglycan staining, and two with striking lymphocyte infiltration in addition to dystrophic change on muscle pathology. Fourteen in 15 patients with SSCD, were shown to have COL6A1, COL6A2 or COL6A3 mutations by NGS analysis; all showed marked distal hyperlaxity and normal intelligence but the overall severity was less than in previously reported patients from other populations. All six patients with merosin deficiency had mutations in LAMA2. They showed relatively uniform phenotype that were compatible with previous studies, except for higher proportion of mental retardation with epilepsy. With reduced alpha-dystroglycan staining, one patient was found to carry mutations in POMT1 while another patient carried mutations in TRAPPC11. LMNA mutations were found in the two patients with inflammatory change on muscle pathology. They were clinically characterized by neck flexion limitation and early joint contracture, but no cardiac problem had developed yet. CONCLUSION: Muscle pathology remains helpful in guiding further molecular analyses by direct sequencing of certain genes or by target capture/NGS as a second-tier diagnostic tool, and is crucial for establishing the genotype-phenotype correlation. We also determined the frequencies of the different types of CMD in our cohort which is important for the development of a specific care system for each disease. Public Library of Science 2017-02-09 /pmc/articles/PMC5300266/ /pubmed/28182637 http://dx.doi.org/10.1371/journal.pone.0170517 Text en © 2017 Liang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Liang, Wen-Chen
Tian, Xia
Yuo, Chung-Yee
Chen, Wan-Zi
Kan, Tsu-Min
Su, Yi-Ning
Nishino, Ichizo
Wong, Lee-Jun C.
Jong, Yuh-Jyh
Comprehensive target capture/next-generation sequencing as a second-tier diagnostic approach for congenital muscular dystrophy in Taiwan
title Comprehensive target capture/next-generation sequencing as a second-tier diagnostic approach for congenital muscular dystrophy in Taiwan
title_full Comprehensive target capture/next-generation sequencing as a second-tier diagnostic approach for congenital muscular dystrophy in Taiwan
title_fullStr Comprehensive target capture/next-generation sequencing as a second-tier diagnostic approach for congenital muscular dystrophy in Taiwan
title_full_unstemmed Comprehensive target capture/next-generation sequencing as a second-tier diagnostic approach for congenital muscular dystrophy in Taiwan
title_short Comprehensive target capture/next-generation sequencing as a second-tier diagnostic approach for congenital muscular dystrophy in Taiwan
title_sort comprehensive target capture/next-generation sequencing as a second-tier diagnostic approach for congenital muscular dystrophy in taiwan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300266/
https://www.ncbi.nlm.nih.gov/pubmed/28182637
http://dx.doi.org/10.1371/journal.pone.0170517
work_keys_str_mv AT liangwenchen comprehensivetargetcapturenextgenerationsequencingasasecondtierdiagnosticapproachforcongenitalmusculardystrophyintaiwan
AT tianxia comprehensivetargetcapturenextgenerationsequencingasasecondtierdiagnosticapproachforcongenitalmusculardystrophyintaiwan
AT yuochungyee comprehensivetargetcapturenextgenerationsequencingasasecondtierdiagnosticapproachforcongenitalmusculardystrophyintaiwan
AT chenwanzi comprehensivetargetcapturenextgenerationsequencingasasecondtierdiagnosticapproachforcongenitalmusculardystrophyintaiwan
AT kantsumin comprehensivetargetcapturenextgenerationsequencingasasecondtierdiagnosticapproachforcongenitalmusculardystrophyintaiwan
AT suyining comprehensivetargetcapturenextgenerationsequencingasasecondtierdiagnosticapproachforcongenitalmusculardystrophyintaiwan
AT nishinoichizo comprehensivetargetcapturenextgenerationsequencingasasecondtierdiagnosticapproachforcongenitalmusculardystrophyintaiwan
AT wongleejunc comprehensivetargetcapturenextgenerationsequencingasasecondtierdiagnosticapproachforcongenitalmusculardystrophyintaiwan
AT jongyuhjyh comprehensivetargetcapturenextgenerationsequencingasasecondtierdiagnosticapproachforcongenitalmusculardystrophyintaiwan